Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management
- 126 Downloads
Adjuvant endocrine therapy (AET) utilization is linked to improved clinical outcomes among breast cancer survivors (BCS); yet, AET adherence rates remain suboptimal. Little is known about provider perspectives regarding barriers and facilitators to AET-related symptom management (SM). In this study, we examined provider perspectives on the barriers and facilitators to AET-related SM among BCS and opportunities for improvement.
We conducted three focus groups (FGs) with a multidisciplinary group of healthcare providers (n = 13) experienced in caring for BCS undergoing AET. We utilized semi-structured discussion guides to elicit provider perspectives on AET-related SM. FGs were audiotaped, transcribed, and analyzed using qualitative software to identify key themes.
Providers described patient-, provider-, and system-level barriers and facilitators to AET-related SM. At the patient-level, barriers included competing demands, limited time/resources, and possible misattribution of some symptoms to AET, while family/social relationships and insurance emerged as important facilitators. Discomfort with SM, limited time, and challenges distinguishing AET-related symptoms from other conditions were key provider-level barriers. Provider-level facilitators included routine symptom documentation and strong provider relationships. Care fragmentation and complexity of the cancer care delivery system were described as system-level barriers; however, survivor clinics were endorsed by providers.
Provider perspectives on AET-related SM can shed light on SM barriers and facilitators spanning multiple levels of the cancer care delivery system. Strategies for improving AET-related SM in BCS include increasing patients’ knowledge and engagement in SM, equipping providers with efficient SM strategies, and improving coordination of symptom-related services through survivorship programs.
KeywordsSymptom management Adjuvant endocrine therapy Provider perspectives Breast cancer Survivorship care
This study was supported by the following funding sources: American Federation for Aging Research/John A. Hartford Foundation, the Magee-Women’s Research Institute and Foundation, the University of Pittsburgh Multidisciplinary Clinical Research Scholars Program–National Institutes of Health Clinical and Translational Science Award (CTSA) (grant number: 05 KL2 RR024154), the National Cancer Institute Cancer Center Support Grant (grant number: P30 CA047904), and the National Cancer Institute Award Diversity Supplement Award (grant number: 3 R01 CA150980-04S1).
Compliance with ethical standards
The University of Pittsburgh’s Institutional Review Board approved this study.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA et al (2015) Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 107(6):djv048. doi: 10.1093/jnci/djv048 CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796. doi: 10.1200/JCO.2009.26.3756 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816. doi: 10.1016/S0140-6736(12)61963-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.American Cancer Society Hormone Therapy for Breast Cancer 2013. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-hormone-therapy. Accessed March 31 2016
- 7.Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128. doi: 10.1200/JCO.2009.25.9655 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg DH et al (2014) Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer 22(4):937–945. doi: 10.1007/s00520-013-2041-y CrossRefPubMedGoogle Scholar
- 17.van Ryn M, Phelan SM, Arora NK, Haggstrom DA, Jackson GL, Zafar SY et al (2014) Patient-reported quality of supportive care among patients with colorectal cancer in the Veterans Affairs Health Care System. J Clin Oncol 32(8):809–815. doi: 10.1200/JCO.2013.49.4302 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Krueger RA, Casey MA (2015) Participants in a focus group focus groups: a practical guide for applied research, 5th edn. SAGE Publications, Inc.Google Scholar
- 26.Boyatzis RE (1998) Transforming qualitative information: thematic analysis and code development. London, & New Delhi SAGE Publications, Thousand OaksGoogle Scholar
- 27.Patton MQ (1990) Qualitative evaluation and research methods, 2nd edn. Newbury Park, Sage PublicationsGoogle Scholar
- 28.Saldana J (2009) An introduction to codes and coding the coding manual for qualitative researchers. SAGE Publications, Los AngelesGoogle Scholar
- 29.In: Levit L, Balogh E, Nass S, Ganz PA, editors. Delivering high-quality cancer care: charting a new course for a system in crisis. Washington (DC)2013.Google Scholar
- 30.Ganz PA (2014) Institute of Medicine report on delivery of high-quality cancer care. J Oncol Pract 10(3):193-195Google Scholar
- 37.Hewitt M, Greenfield S, Stovall E (2005) Committee on Cancer Survivorship: improving care and quality of life, Institute of Medicine and National Research Council. From cancer patient to cancer survivor: lost in transition.Google Scholar
- 44.American College of Surgeons Commission on Cancer: cancer program standards (2016 Edition). 2016. https://www.facs.org/quality-programs/cancer/coc/standards. Accessed April 7 2016.
- 45.Turner K, Samuel CA, Donovan HA, Beckjord E, Cardy A, Dew MA, van Londen GJ (2016) Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management. Support Care Cancer 25(4):1055-1061. doi: 10.1007/s00520-016-3491-9